TICKERNERD
Menu
INTSINTSHealthcare · Biotechnology

INTS Stock Forecast: Intensity Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 13 Nov 2026
$3.03
−2.26% on the day

The 6 Wall Street analysts covering Intensity Therapeutics, Inc. hold a median 12-month price target of $18 — +477.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 30 of 100 as at 13 Nov 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$10.2M
Ticker Nerd rank
30/ 100
Median analyst target
$18
Analysts covering
6
Revenue$0.0
Operating income−$3.1M
Net income−$3.0M
Free cash flow−$2.3M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+1.0%
1M
−14.6%
YTD
−70.4%
1Y
−74.6%
From 52W high
−79.5%
From 52W low
+1.0%
$3
$15
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

INTS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Intensity Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 13 Nov 2026
30/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
91
Volatility
74
Accruals
61
Quality
41
Issuance
33
Growth
32
Momentum
29
Value
26
Revisions
26

Size (91): Smaller than most of the companies we track.

Revisions (26): Analysts have, on balance, been cutting their forecasts.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

INTS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on INTS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$5$10$15$20$25$30$35Jan 26Apr 26Jul 26Oct 26INTSHigh $32Median $18Low $7

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says6 analysts
6 Buy0 Hold0 Sell
Low $7Median $18High $32

The green dot is the last close — the median target sits +477.6% from it.

Recent analyst actionsNewest first

Of the 15 most recent actions, 1 moved their price target up and 2 moved it down.

DateFirmActionRatingTarget
6 Nov 2026StoneXMaintainsSpeculative Buy$12 → $8.00
18 Aug 2026HC Wainwright & Co.MaintainsBuy$5.00 → $7.00
18 Aug 2026HC Wainwright & Co.MaintainsBuy—
20 Aug 2025BenchmarkMaintainsSpeculative Buy$4.00 → $1.50
20 Aug 2025BenchmarkMaintainsSpeculative Buy—
12 Aug 2025Brookline CapitalUpgradeBuy—
13 Jan 2025Alliance Global PartnersInitiatesBuy—
21 Nov 2024HC Wainwright & Co.ReiteratesBuy—
31 Oct 2024HC Wainwright & Co.InitiatesBuy—
11 July 2024BenchmarkReiteratesSpeculative Buy—
16 May 2024BenchmarkReiteratesSpeculative Buy—
21 Mar 2024BenchmarkReiteratesSpeculative Buy—
14 Nov 2023BenchmarkReiteratesSpeculative Buy—
24 Aug 2023BenchmarkReiteratesSpeculative Buy—
18 July 2023BenchmarkInitiatesSpeculative Buy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

INTS appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

INTS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 13 Nov 2026, Intensity Therapeutics, Inc. returned −74.6% against +13.4% for the S&P 500, dividends included.

INTS vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Jan 26Apr 26Jul 26Oct 26INTSS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

INTS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
3
Fundamentals

Intensity Therapeutics, Inc. (INTS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.4×

Cheaper than 81% of US stocks

Price / sales
—
Price / book
1.3×

Cheaper than 59% of US stocks

EV / EBITDA
−0.1×

Cheaper than 64% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−161.8%

Higher than 9% of US stocks

Return on assets
−77.8%

Higher than 4% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Intensity Therapeutics, Inc. (INTS) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Intensity Therapeutics, Inc. has a market value of $10.2M and an enterprise value of $1.8M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$11.2M.

  • Free cash flow in the twelve months to 30 June 2026: −$9.0M.

  • Shares outstanding: 2.9M.

  • Trailing P/E: −0.4×; forward P/E: −1.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Intensity Therapeutics, Inc. employs 5 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 14 Nov 2026

Data provided by Twelve Data

Peers

INTS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
INTSIntensity Therapeutics, Inc.$10.2M30
MTRIMentari Therapeutics, Inc.$10.2M31
GDTCCytoMed Therapeutics Ltd.$9.8M32
TCRXTScan Therapeutics, Inc.$10.5M45
LEXXLexaria Bioscience Corp.$9.4M19
HINDVyome Holdings, Inc.$11.1M27
PTNPalatin Technologies, Inc.$11.1M40

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Intensity Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest INTS news & analysis

Intensity Therapeutics, Inc. (INTS) Q3 2026 Earnings Call Transcript

Seeking Alpha · 7 Nov 2026neutral

Intensity Therapeutics held its third-quarter 2026 financial results conference call on November 5, 2026. The excerpt identifies company executives and participating analysts but provides no discussion details or financial results.

Why it matters — The call concerns INTS’s quarterly results, but the excerpt does not include enough information to characterize the results or management’s commentary.

Intensity Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

PRNewsWire · 5 Nov 2026neutral

Intensity Therapeutics reported that enrollment resumed at a limited number of U.S. sites in its Phase 3 INVINCIBLE-3 soft tissue sarcoma study and that enrollment and treatment resumed in its Phase 2 INVINCIBLE-4 presurgical TNBC study during the third quarter of 2026. The company reported $8.5 million in cash and cash equivalents as of September 30, 2026.

Why it matters — The update covers activity in two clinical studies and the company’s reported cash position.

Intensity Therapeutics to Announce Third Quarter 2026 Financial Results on November 5, 2026

PRNewsWire · 30 Oct 2026neutral

Intensity Therapeutics said it will report third-quarter 2026 financial results before the market opens on November 5, 2026. The company will hold a conference call at 8 a.m. ET that day to review the results and provide a corporate update.

Why it matters — INTS watchers can note the scheduled date and time for the company’s financial results and corporate update.

Intensity Therapeutics, Inc. to Present INVINCIBLE-4 Neoadjuvant Triple-Negative Breast Cancer Study Data for the First Seven (7) Patients After INT230-6 Treatment (Cohort A) in an ePoster Presentation at the European Society of Medical Oncology (ESMO) Meeting

PRNewsWire · 23 Oct 2026positive

Intensity Therapeutics said the first seven patients in Cohort A of the INVINCIBLE-4 study achieved a pathological complete response in the breast and affected lymph nodes in five cases (71%). No invasive breast cancer cells were detected in the axillary lymph nodes of six patients; results will be presented in an ePoster at the ESMO 2026 Virtual Congress.

Why it matters — The early cohort data provide an initial report on outcomes with INT230-6 plus standard-of-care treatment in neoadjuvant triple-negative breast cancer.

Intensity Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

PRNewsWire · 8 Sept 2026neutral

Intensity Therapeutics, Inc. announced it will participate in the H.C. Wainwright 28th Annual Global Investment Conference. The company, a late-stage clinical biotechnology firm developing intratumoral cancer therapies, shared the news via press release on September 8, 2026.

Why it matters — Conference participation gives INTS investors an opportunity for company management to present its clinical programs and engage with the investment community, potentially raising visibility for the stock.

FAQ

Frequently asked questions about INTS stock

What is the INTS stock price forecast for 2026-2027?

The 6 Wall Street analysts covering Intensity Therapeutics, Inc. have a median 12-month price target of $18, with estimates ranging from $7 to $32. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is INTS stock a buy right now?

Of the 6 analysts covering Intensity Therapeutics, Inc., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Intensity Therapeutics, Inc. 30 out of 100 across roughly 4,600 US stocks as at 13 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank INTS?

As at 13 Nov 2026, Intensity Therapeutics, Inc. ranks 30 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (91 of 100).

Will INTS stock go up?

No one can know that. What the data says: the median 12-month target from 6 analysts implies +477.6% from the last close, and Ticker Nerd's factor model ranks Intensity Therapeutics, Inc. 30 out of 100 as at 13 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the INTS stock forecast for 2030?

No analyst covering Intensity Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for INTS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7 to $32 over the next 12 months.

How has INTS stock performed over the past year?

Intensity Therapeutics, Inc. returned -74.6% over the 12 months to 13 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Intensity Therapeutics, Inc. do?

Intensity Therapeutics, Inc. is a late-stage clinical biotechnology company focused on developing intratumoral cancer therapies for solid tumors.

What is the latest news on INTS?

The most recent item we track (Seeking Alpha, 7 Nov 2026): "Intensity Therapeutics, Inc. (INTS) Q3 2026 Earnings Call Transcript". Intensity Therapeutics held its third-quarter 2026 financial results conference call on November 5, 2026. The excerpt identifies company executives and participating analysts but provides no discussion details or financial results.

Company

About Intensity Therapeutics, Inc.

Intensity Therapeutics, Inc. is a late-stage clinical biotechnology company focused on developing intratumoral cancer therapies for solid tumors. Its lead product candidate, INT230-6, is designed to be injected directly into tumors to help destroy cancer cells locally while also promoting a broader immune response against cancer throughout the body. The company’s platform centers on proprietary drug-conjugation technology that combines active anti-cancer agents with molecules that improve dispersion within tumors and cellular uptake. Intensity Therapeutics is currently advancing programs in cancers such as soft tissue sarcoma and triple-negative breast cancer, with an emphasis on addressing both localized disease and metastatic spread. Headquartered in Shelton, Connecticut, Intensity Therapeutics operates within the oncology biotechnology segment, where its work contributes to the development of novel immune-based treatment approaches for patients with solid tumor cancers.

CEO Mr. Lewis H. Bender M.A., M.B.A., M.S. · 5 employees · United States · https://intensitytherapeutics.com